Work

Evaluating the clinical utility of ctDNA testing to identify molecular cancer progression – lessons from SERENA-6

Year: 2026

Type: article

Abstract: Mutation identification via circulating tumor DNA (ctDNA) to select appropriate therapy has demonstrated clinical utility in metastatic breast cancer (MBC). SERENA-6 demonstrated the efficacy and tolerability of camizestrant in HR + /HER2-, ESR-1 mutated MBC after an AI/CDK 4/6 inhibitor. However, it remains unclear whether switching therapy at the time of ctDNA-detected emergence of ESR-1 mutations (“molecular progression”) improves long-term outcomes over switching therapy at the time of traditional anatomic/clinical progression.

Source: npj Breast Cancer

DOI: 10.1038/s41523-026-00894-4

Authors: Eleanor Taranto, Angela DeMichele

Institutions: Abramson Cancer Center, University of Pennsylvania

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,790